SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A minor change in the total revenue was seen in the September 2024 quarter. The total revenue for the quarter stood at Rs. 10000.50 millions against Rs. 9533.80 millions during year ago period.Net profit stood at Rs. 2486.90  millions  compared to Rs. 2155.40 millions in the corresponding previous quarter,high by 15.38%.Operating profit for the quarter ended September 2024 rose to 3511.40 millions as compared to 3150.50 millions of corresponding quarter ended September 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 10000.50 9533.80 4.90 18110.50 16914.00 7.07 34072.50 32163.40 5.94
Other Income 321.90 284.70 13.07 680.40 652.70 4.24 1234.80 1015.20 21.63
PBIDT 3511.40 3150.50 11.46 6164.10 4931.00 25.01 10241.30 9009.30 13.67
Interest 2.70 4.30 -37.21 6.40 7.10 -9.86 18.00 18.10 -0.55
PBDT 3555.60 3146.20 13.01 6204.60 5096.90 21.73 8787.20 8981.50 -2.16
Depreciation 168.60 181.10 -6.90 332.70 344.70 -3.48 696.80 657.70 5.94
PBT 3387.00 2965.10 14.23 5871.90 4752.20 23.56 8090.40 8323.80 -2.80
TAX 900.10 809.70 11.16 1568.50 1291.00 21.49 2243.50 2276.80 -1.46
Deferred Tax -74.50 -96.30 -22.64 -39.40 -141.30 -72.12 -113.60 -183.70 -38.16
PAT 2486.90 2155.40 15.38 4303.40 3461.20 24.33 5846.90 6047.00 -3.31
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 35.11 33.05 6.25 34.04 29.15 16.75 30.06 28.01 7.31

Glaxosmithkline Phar Share Price

2412.30 6.05 (0.25%)
16-Apr-2026 10:21 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.00
Dr. Reddys Lab 1221.50
Cipla 1229.65
Zydus Lifesciences 940.35
Lupin 2315.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×